{"id":"velcade-administered-by-intravenous-infusion","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Peripheral neuropathy"},{"rate":"25-40","effect":"Thrombocytopenia"},{"rate":"15-30","effect":"Neutropenia"},{"rate":"20-30","effect":"Anemia"},{"rate":"40-50","effect":"Nausea"},{"rate":"30-40","effect":"Diarrhea"},{"rate":"30-40","effect":"Fatigue"},{"rate":"15-25","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Bortezomib selectively and reversibly inhibits the 26S proteasome, a cellular complex responsible for protein degradation. By blocking proteasome function, the drug causes accumulation of pro-apoptotic proteins and disrupts cell cycle regulation, leading to cancer cell death. This mechanism is particularly effective in multiple myeloma and certain lymphomas where proteasome inhibition triggers rapid apoptosis.","oneSentence":"VELCADE (bortezomib) is a proteasome inhibitor that blocks the degradation of proteins, causing cancer cells to accumulate toxic protein levels and undergo apoptosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:27.249Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"},{"name":"Mantle cell lymphoma"}]},"trialDetails":[{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT01453088","phase":"PHASE2","title":"Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2010-06-24","conditions":"Multiple Myeloma","enrollment":63},{"nctId":"NCT02773030","phase":"PHASE1, PHASE2","title":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2016-10-14","conditions":"Multiple Myeloma","enrollment":466},{"nctId":"NCT05257083","phase":"PHASE3","title":"A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2023-10-10","conditions":"Multiple Myeloma","enrollment":759},{"nctId":"NCT07149857","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-10-03","conditions":"Multiple Myeloma","enrollment":60},{"nctId":"NCT04923893","phase":"PHASE3","title":"A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-08-19","conditions":"Multiple Myeloma","enrollment":743},{"nctId":"NCT05137054","phase":"PHASE1","title":"A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-08-17","conditions":"Multiple Myeloma","enrollment":317},{"nctId":"NCT02718833","phase":"PHASE2","title":"A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2016-06-21","conditions":"Multiple Myeloma","enrollment":52},{"nctId":"NCT03829371","phase":"PHASE4","title":"STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Turin, Italy","startDate":"2019-01-03","conditions":"Multiple Myeloma","enrollment":450},{"nctId":"NCT04091126","phase":"PHASE1","title":"Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2019-12-18","conditions":"Multiple Myeloma","enrollment":118},{"nctId":"NCT02195479","phase":"PHASE3","title":"A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-12-09","conditions":"Multiple Myeloma","enrollment":706},{"nctId":"NCT06497738","phase":"","title":"A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-05-01","conditions":"Multiple Myeloma","enrollment":112},{"nctId":"NCT03314181","phase":"PHASE2","title":"A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2018-04-02","conditions":"Multiple Myeloma","enrollment":156},{"nctId":"NCT07045909","phase":"PHASE2","title":"Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)","status":"RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2025-06-30","conditions":"De Novo Multiple Myeloma, Anitocabtagene Autoleucel","enrollment":30},{"nctId":"NCT01998971","phase":"PHASE1","title":"A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02-18","conditions":"Multiple Myeloma","enrollment":240},{"nctId":"NCT04304144","phase":"PHASE2","title":"A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-03-18","conditions":"AL Amyloidosis","enrollment":25},{"nctId":"NCT02375555","phase":"PHASE2","title":"Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-05-07","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT03234972","phase":"PHASE3","title":"A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-30","conditions":"Multiple Myeloma","enrollment":213},{"nctId":"NCT02440464","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2015-08","conditions":"Multiple Myeloma","enrollment":57},{"nctId":"NCT01568866","phase":"PHASE3","title":"Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-06-20","conditions":"Multiple Myeloma","enrollment":929},{"nctId":"NCT00784823","phase":"PHASE1, PHASE2","title":"Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma","status":"COMPLETED","sponsor":"Hackensack Meridian Health","startDate":"2007-01","conditions":"Multiple Myeloma","enrollment":32},{"nctId":"NCT05052970","phase":"PHASE1","title":"Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM","status":"UNKNOWN","sponsor":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","startDate":"2021-10-20","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":60},{"nctId":"NCT00765102","phase":"PHASE2","title":"Trial of Romidepsin and Bortezomib for Multiple Myeloma","status":"TERMINATED","sponsor":"Celgene","startDate":"2008-09-01","conditions":"Multiple Myeloma","enrollment":32},{"nctId":"NCT00401843","phase":"PHASE2","title":"A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2006-11-28","conditions":"Multiple Myeloma","enrollment":307},{"nctId":"NCT03044353","phase":"PHASE2","title":"Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-07-10","conditions":"Amyloidosis","enrollment":7},{"nctId":"NCT00369707","phase":"PHASE2","title":"Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2006-08-09","conditions":"Non-Hodgkin's Lymphoma","enrollment":42},{"nctId":"NCT01818752","phase":"PHASE3","title":"Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-07-08","conditions":"Multiple Myeloma","enrollment":955},{"nctId":"NCT03168100","phase":"PHASE2","title":"2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma","status":"WITHDRAWN","sponsor":"University of Arkansas","startDate":"2017-10-01","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT02208037","phase":"PHASE2","title":"Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2014-08","conditions":"Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia","enrollment":279},{"nctId":"NCT00670423","phase":"PHASE1","title":"A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation","status":"COMPLETED","sponsor":"Jennifer E. Schwartz","startDate":"2008-05-16","conditions":"Graft vs Host Disease, Peripheral Blood Stem Cell Transplantation, Transplantation, Homologous","enrollment":27},{"nctId":"NCT00620295","phase":"PHASE1","title":"Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2007-03","conditions":"Breast Cancer, Colorectal Cancer, Head and Neck Cancer","enrollment":17},{"nctId":"NCT00473590","phase":"PHASE2","title":"A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-06","conditions":"Multiple Myeloma","enrollment":102},{"nctId":"NCT01359657","phase":"PHASE1","title":"Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-09","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT01160484","phase":"PHASE2","title":"Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Oncotherapeutics","startDate":"2009-09","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT00911859","phase":"PHASE2","title":"A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2009-06","conditions":"Multiple Myeloma","enrollment":118},{"nctId":"NCT01009840","phase":"PHASE2","title":"IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-05","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT00590603","phase":"PHASE1","title":"Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Duke University","startDate":"2008-07","conditions":"Multiple Myeloma","enrollment":25},{"nctId":"NCT00920855","phase":"PHASE1, PHASE2","title":"Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Cephalon","startDate":"2009-06","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT00237627","phase":"PHASE1, PHASE2","title":"Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2001-05","conditions":"Breast Cancer, Leukemia, Lymphoma","enrollment":107},{"nctId":"NCT00636792","phase":"PHASE2","title":"A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2008-02","conditions":"Follicular Lymphoma","enrollment":73},{"nctId":"NCT00722566","phase":"PHASE3","title":"A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2008-07","conditions":"Multiple Myeloma","enrollment":222}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"VELCADE Administered by intravenous infusion","genericName":"VELCADE Administered by intravenous infusion","companyName":"Millennium Pharmaceuticals, Inc.","companyId":"millennium-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VELCADE (bortezomib) is a proteasome inhibitor that blocks the degradation of proteins, causing cancer cells to accumulate toxic protein levels and undergo apoptosis. Used for Multiple myeloma, Mantle cell lymphoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}